Work

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Year: 2012

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(12)70063-3

Authors: Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesús Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H Zimmermann, Carla Visseren-Grul, Cesare Gridelli

Institutions: Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Azienda Ospedaliera San Camillo-Forlanini, Institutul Oncologic Bucuresti, Heidelberg University, Centre Hospitalier Universitaire de Montpellier, Azienda Ospedaliera San Gerardo, Centre Hospitalier du Mans, Jawaharlal Nehru Cancer Hospital and Research Centre, University Medical Center Hamburg-Eppendorf, LungenClinic Grosshansdorf, Eli Lilly (United States), Eli Lilly (Netherlands), Azienda Ospedaliera S.Giuseppe Moscati

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Eli Lilly and Company

OpenAlex ID: W2005244154

FWCI: 62.82

Cites: 33

Cited by: 609

Related to: 10